Abstract: This invention relates to novel potassium channel activators and their acid addition salts. The compounds of the invention as potassium channel activators/openers have therapeutic value in a number of physiological areas such as hypertension, cardiac ischemia, cerebral ischemia, broncho constriction and neurodegenerative diseases. Pharmaceutical compositions are proposed for the compounds which are of the following formulae: ##STR1## wherein: R is H or OH;- - - the dotted line at position 3,4 represents the presence or absence of a double bond. ##STR2## the pharmaceutically acceptable acid addition salts thereof, with the provisos that:a) R is H when 3,4 is a double bond; andb) R is OH when 3,4 is a single bond.

Abstract: Proteins having an epidermal growth factor-like binding region, such as thrombomodulin, may be recovered and purified on a anion exchange resin, such as a polyethyleneimine resin. Conditioned medium containing recombinantly produced protein is applied to the resin under conditions of pH and ionic strength selected to result in specific binding of the protein to the resin. The column is then washed to remove non-bound proteins and bound proteins other than the desired protein to be separated. The desired protein is then eluted from the column and collected in a medium. Further purification, concentration, and other treatment of the protein may be performed by conventional techniques.

Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host, IFN, either constitutive or inductive.

Abstract: This invention relates to novel 5-pyrimidineamine derivatives. The compounds of the invention exhibit cardiovascular properties, particularly mixed vasodilative, selective venous and arterial dilation. Pharmaceutical compositions are proposed for the compounds.

Abstract: An arrangement for retaining blister pack tablets comprises a container with at least a front cover and a rear cover with a blister pack sandwiched therebetween and visible through a window in the front cover. The blister pack includes indicia thereon indicating the order in which the tablets should be taken and the container includes a pointer identifying the first tablet in the array of tablets to be consumed. Preferably, the container includes a daily calendar in the form of a loop or cylinder which is moveable with respect to the container so that a desired starting day can be selected by the user or prescriber. Preferably, the loop or cylinder is lockable in its selected position. In accordance with two embodiments of the invention, front and rear lids are pivoted to the front and rear covers, respectively, to conceal the blister pack until it is necessary to take a tablet.

Abstract: A circular tissue recording chamber has a cavity therein for retaining tissue or cell samples immersed in a liquid bath. The temperature of the bath is maintained at a selected level by a transparent heater positioned beneath the bath, wherein the heater is comprised of a grid of fine wires supported on a transparent mylar substrate. Liquid is introduced into the bath through a serpentine passageway also in proximity with the heater, whereby the temperature of the liquid is raised to that of the bath as it traverses the passageway. The recording chamber has a thickness of approximately 1 cm so as to be readily usable with a high magnification microscope.

Abstract: A procedure for the preparation of the solubilized and purified gastrin releasing peptide receptor, in an active form, from a gastrin releasing peptide receptor source such as Swiss 3T3 fibroblasts.

Abstract: This invention relates to novel imidazoquinoxalinones and their aza analogs and to a process for their preparation. The compounds of this invention have been found to have inodilatory, vasodilatory, venodilatory and other pharmacologic effects.

Abstract: The present invention relates to the isolation and restoration of biological activity to inactive proteins, that is solubilizing, renaturing and restoring activity to proteins which have been partially denatured or inactivated, e.g. during their synthesis in a host cell, such as E. coli, or during isolation. In particular this invention relates to both a means for extracting insoluble eukaryotic proteins from bacteria and to an efficient process for producing active chymosin from an insoluble chymosin precursor isolated from genetically engineered bacteria.

Abstract: This invention relates to novel imidazoquinoxalinones and their aza analogs and to a process for their preparation. The compounds of this invention have been found to have inodilatory, vasodilatory, venodilatory and other pharmacologic effects.

Abstract: This invention relates generally to recombinant DNA techniques and to the expression of mammalian polypeptides in genetically engineered eukaryotic cells. Specifically, the invention relates to preferred plasmid constructs and methods that increase levels of expression of a cloned gene product. These preferred plasmids have selectable and nonselected gene cassettes adjacent to each other and oriented in the opposite direction for transcription. Such an orientation enhances overall levels of expression for the nonselected gene. Further, this invention relates to gene products expressed at these very high levels by the herein described method, and to the eukaryotic cells derived thereby.

Abstract: This invention relates to novel 3,4,5,6-tetrahydro-2H-1,7,4-benzodioxazonines and their pharmaceutically acceptable salts. The compounds of the invention are cardiovascular agents and especially Class III antiarrhythmic agents.

Abstract: This invention relates to novel pyrrolo[1,2-c]imidazolones and their pharmaceutically acceptable salts. The compounds of the invention are PDE inhibitors with primarily cardiovascular effects especially cardiotonic effects.

Abstract: A tablet container having a cover and sliding tray is used for dispensing birth control tablets for either a twenty-one-day or twenty-eight-day cycle. Normally, the tray does not slide completely out of the cover and is stabilized with respect thereto when open. The case resembles a cosmetic compact and is reuseable in that once birth control tablets contained in a blister pack are used up, a new blister pack may easily be inserted.

Abstract: Orally active prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2 -one are disclosed. Pharmaceutical formulations containing such compounds are also provided.

Abstract: A system and apparatus for containing and dispensing medications in a prescribed manner, and for reducing the possibility of incorrect dosages being taken and/or medication being taken at the wrong time of the day. A tray contains plural rows and columns of cavities, and each cavity is adapted to contain medication therein. The cavities include structure dividing them into two parts. A first part is open to the user to enable the user to place medication therein and to remove medication therefrom. A second part is closed off from direct access by the user in semi-permanent fashion by a transparent enclosure and is used to contain in a preferred embodiment, an exemplification of a appropriate dosage of medication to be taken. For example, if five green pills are to be taken, the enclosed portion will contain five green pills viewable through the transparent enclosure. The dose example of medication contained therein is the dose amount and type medication to be placed in each open cavity structure each day.

Abstract: A novel, orally administrable pro-drug form of dobutamine of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The compound N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and methods for its manufacture and use are described herein. The compound is a cardiotonic agent useful primarily in the treatment of congestive heart failure.

Abstract: 3-Phenoxy-2-hydroxypropylamines having an N-benzimidazolyalkyl substituent and similar compounds are described herein. They are obtained by the reaction of the appropriate imidazole-1-alkanamine with an epoxide, and they are useful primarily as .beta..sub.1 -agonists/.beta.-sympathomimetic agents.